Korean J Pain.  2011 Sep;24(3):164-168. 10.3344/kjp.2011.24.3.164.

Obturator Nerve Block with Botulinum Toxin Type B for Patient with Adductor Thigh Muscle Spasm: A Case Report

• Choi EJ
• Byun JM
• Nahm FS
• Lee PB

• KMID: 2278106
• DOI: http://doi.org/10.3344/kjp.2011.24.3.164

Abstract

Obturator nerve block has been commonly used for pain management to prevent involuntary reflex of the adductor thigh muscles. One of several options for this block is chemical neurolysis. Neurolysis is done with chemical agents. Chemical agents used in the neurolysis of the obturator nerve have been alcohol, phenol, and botulinum toxin. In the current case, a patient with spasticity of the adductor thigh muscle due to cervical cord injury had obturator nerve neurolysis done with botulinum toxin type B (BoNT-B). Most of the previous studies have used BoNT-A with only a few reports that have used BoNT-B. BoNT-B has several advantages and disadvantages over BoNT-A. Thus, we report herein a patient who successfully received obturator nerve neurolysis using BoNT-B to treat adductor thigh muscle spasm.

Keyword

botulinum toxin type B; obturator nerve; spasticity

MeSH Terms

Botulinum Toxins
Botulinum Toxins, Type A
Humans
Muscle Spasticity
Muscles
Nerve Block
Obturator Nerve
Pain Management
Phenol
Reflex
Spasm
Thigh
Botulinum Toxins
Botulinum Toxins, Type A
Phenol

Figure

• 

  Fig. 1 Injection of anterior branch of obturator nerve visualized along focal hyperechoic interfascial line. An anterior branch of obturator nerve is located adductor longus muscle (ALM) and adductor brevis muscles (ABM).

• 

  Fig. 2 Injection of posterior branch of obturator nerve. Needle tip positioned between adductor brevis (ABM) and adductor magnus muscles (AMM).

Reference

1. O'Brien CF. Treatment of spasticity with botulinum toxin. Clin J Pain. 2002; 18(6 Suppl):S182–S190. PMID: 12569967.

2. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004; 28:140–175. PMID: 15276195.

3. Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol. 2005; 53:3–9. PMID: 15650306.

4. Calderón-González R, Calderón-Sepúlveda RF. Clinical treatment (non surgical) of spasticity in cerebral palsy. Rev Neurol. 2002; 34:1–6. PMID: 11988886.

5. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner. 1964; 192:540–542. PMID: 14143329.

6. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980; 87:1044–1049. PMID: 7243198.

7. Truong DD, Stenner A, Reichel G. Current clinical applications of botulinum toxin. Curr Pharm Des. 2009; 15:3671–3680. PMID: 19925419.

8. Grunfeld A, Murray CA, Solish N. Botulinum toxin for hyperhidrosis: a review. Am J Clin Dermatol. 2009; 10:87–102. PMID: 19222249.

9. Kharkar S, Ambady P, Yedatore V, Schwartzman RJ. Intramuscular botulinum toxin A (BtxA) in complex regional pain syndrome. Pain Physician. 2011; 14:311–316. PMID: 21587336.

10. Lim SJ, Park HJ, Lee SH, Moon DE. Ganglion impar block with botulinum toxin type a for chronic perineal pain -a case report-. Korean J Pain. 2010; 23:65–69. PMID: 20552077.

11. Aoki KR. Pharmacology and immunology of botulinum toxin type A. Clin Dermatol. 2003; 21:476–480. PMID: 14759579.

12. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005; 65:1423–1429. PMID: 16275831.

13. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994; 9:213–217. PMID: 8196686.

14. Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord. 2005; 20:1152–1160. PMID: 15954134.

15. Callaway JE. Botulinum toxin type B (Myobloc): pharmacology and biochemistry. Clin Dermatol. 2004; 22:23–28. PMID: 15158541.

16. Akkaya T, Unlu E, Alptekin A, Gumus HI, Umay E, Cakci A. Neurolytic phenol blockade of the obturator nerve for severe adductor spasticity. Acta Anaesthesiol Scand. 2010; 54:79–85. PMID: 19839948.

17. Al-Saleem FH, Ancharski DM, Ravichandran E, Joshi SG, Singh AK, Gong Y, et al. The role of systemic handling in the pathophysiologic actions of botulinum toxin. J Pharmacol Exp Ther. 2008; 326:856–863. PMID: 18539649.

18. Figgitt DP, Noble S. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Drugs. 2002; 62:705–722. PMID: 11893235.

19. Callaway JE, Arezzo JC, Grethlein AJ. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Semin Cutan Med Surg. 2001; 20:127–136. PMID: 11474745.

20. Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J Rehabil Med. 2005; 37:252–257. PMID: 16024483.